Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MBOT NASDAQ:NYXH OTCMKTS:POSC NASDAQ:SGHT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBOTMicrobot Medical$4.05+4.2%$3.10$0.85▼$4.67$184.23M1.223.45 million shs3.55 million shsNYXHNyxoah$5.28-4.9%$6.97$5.28▼$11.87$179.84M1.6102,617 shs60,185 shsPOSCPositron$1.60+5.3%$1.63$0.92▼$2.94$50.25M0.4419,796 shs13,720 shsSGHTSight Sciences$3.49-3.6%$3.77$2.03▼$7.03$182.77M2.46192,610 shs75,126 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBOTMicrobot Medical+8.96%+15.43%+24.68%+66.24%+319.36%NYXHNyxoah-0.36%-2.63%-17.04%-26.39%-26.88%POSCPositron+2.01%-1.94%-13.04%-3.18%+50.50%SGHTSight Sciences+6.16%-2.95%-14.82%-12.35%-44.98%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMBOTMicrobot Medical$4.05+4.2%$3.10$0.85▼$4.67$184.23M1.223.45 million shs3.55 million shsNYXHNyxoah$5.28-4.9%$6.97$5.28▼$11.87$179.84M1.6102,617 shs60,185 shsPOSCPositron$1.60+5.3%$1.63$0.92▼$2.94$50.25M0.4419,796 shs13,720 shsSGHTSight Sciences$3.49-3.6%$3.77$2.03▼$7.03$182.77M2.46192,610 shs75,126 shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMBOTMicrobot Medical+8.96%+15.43%+24.68%+66.24%+319.36%NYXHNyxoah-0.36%-2.63%-17.04%-26.39%-26.88%POSCPositron+2.01%-1.94%-13.04%-3.18%+50.50%SGHTSight Sciences+6.16%-2.95%-14.82%-12.35%-44.98%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMBOTMicrobot Medical 2.50Moderate Buy$12.00196.00% UpsideNYXHNyxoah 3.00Buy$15.00184.09% UpsidePOSCPositron 0.00N/AN/AN/ASGHTSight Sciences 2.43Hold$4.4226.55% UpsideCurrent Analyst Ratings BreakdownLatest POSC, MBOT, NYXH, and SGHT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/11/2025MBOTMicrobot MedicalHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $12.008/28/2025SGHTSight SciencesNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold8/21/2025MBOTMicrobot MedicalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/21/2025SGHTSight SciencesCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$3.60 ➝ $4.508/8/2025SGHTSight SciencesLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$3.00 ➝ $5.007/15/2025SGHTSight SciencesMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$3.00 ➝ $4.006/18/2025SGHTSight SciencesPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$3.50 ➝ $4.00(Data available from 9/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMBOTMicrobot MedicalN/AN/AN/AN/A$0.17 per shareN/ANYXHNyxoah$4.89M36.78N/AN/A$3.60 per share1.47POSCPositron$590K85.17N/AN/A($0.04) per share-40.00SGHTSight Sciences$79.87M2.29N/AN/A$1.72 per share2.03Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMBOTMicrobot Medical-$11.44M-$0.58N/AN/AN/AN/A-76.27%-67.54%11/12/2025 (Estimated)NYXHNyxoah-$64.10M-$2.30N/AN/AN/A-1,541.84%-79.18%-54.92%11/5/2025 (Estimated)POSCPositron-$2.39M-$0.12N/A∞N/A-592.35%-419.44%-79.38%N/ASGHTSight Sciences-$51.51M-$0.96N/AN/AN/A-64.23%-59.38%-36.43%11/6/2025 (Estimated)Latest POSC, MBOT, NYXH, and SGHT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025NYXHNyxoah-$0.62-$0.63-$0.01-$0.63$1.33 million$1.58 million8/12/2025Q2 2025MBOTMicrobot Medical-$0.08-$0.10-$0.02-$0.10$1.00 millionN/A8/7/2025Q2 2025SGHTSight Sciences-$0.25-$0.23+$0.02-$0.23$18.18 million$19.56 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMBOTMicrobot MedicalN/AN/AN/AN/AN/ANYXHNyxoahN/AN/AN/AN/AN/APOSCPositronN/AN/AN/AN/AN/ASGHTSight SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMBOTMicrobot MedicalN/A12.0612.06NYXHNyxoah0.292.632.38POSCPositronN/A1.931.37SGHTSight Sciences0.5710.019.49Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMBOTMicrobot Medical16.30%NYXHNyxoahN/APOSCPositronN/ASGHTSight Sciences55.51%Insider OwnershipCompanyInsider OwnershipMBOTMicrobot Medical4.74%NYXHNyxoah17.11%POSCPositron17.20%SGHTSight Sciences30.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMBOTMicrobot Medical2045.55 million43.39 millionOptionableNYXHNyxoah11034.06 million28.23 millionNot OptionablePOSCPositron2031.41 million26.00 millionNot OptionableSGHTSight Sciences21052.37 million36.19 millionOptionablePOSC, MBOT, NYXH, and SGHT HeadlinesRecent News About These CompaniesSight Sciences, Inc. (SGHT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 10 at 6:03 PM | seekingalpha.comSight Sciences, Inc. (NASDAQ:SGHT) Receives $4.42 Average Target Price from AnalystsSeptember 10 at 2:33 AM | americanbankingnews.comSight Sciences, Inc.: Sight Sciences Announces the OMNI Surgical System to be Included in UnitedHealthcare's Expanded Coverage of Glaucoma Surgical TreatmentsSeptember 9 at 10:10 AM | finanznachrichten.deSight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare’s® Expanded Coverage of Glaucoma Surgical TreatmentsSeptember 9 at 10:10 AM | finance.yahoo.comSight Sciences Announces the OMNI® Surgical System to be Included in UnitedHealthcare's® Expanded Coverage of Glaucoma Surgical TreatmentsSeptember 9 at 7:05 AM | globenewswire.comSight Sciences, Inc. (NASDAQ:SGHT) Receives Consensus Rating of "Hold" from AnalystsSeptember 8, 2025 | marketbeat.comSight Sciences (NASDAQ:SGHT) Downgraded to "Sell" Rating by Wall Street ZenSeptember 8, 2025 | marketbeat.comSight Sciences (NASDAQ:SGHT) Stock Rating Lowered by Wall Street ZenSeptember 7, 2025 | americanbankingnews.comSight Sciences Announces Recognition of the TearCare® System in TFOS DEWS III Global Dry Eye Guidelines Published in AJOSeptember 2, 2025 | globenewswire.comSight Sciences, Inc. $SGHT Shares Purchased by Long Focus Capital Management LLCSeptember 1, 2025 | marketbeat.comSight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare ConferenceAugust 26, 2025 | globenewswire.comWhat 4 Analyst Ratings Have To Say About Sight SciencesAugust 22, 2025 | benzinga.comSight Sciences price target raised to $4.50 from $3.60 at CitiAugust 21, 2025 | msn.comSight Sciences, Inc. (NASDAQ:SGHT) Given Average Recommendation of "Hold" by BrokeragesAugust 14, 2025 | marketbeat.comSight Sciences’ Earnings Call: Balancing Growth and ChallengesAugust 13, 2025 | msn.comLake Street Upgrades Sight Sciences (SGHT)August 11, 2025 | msn.comSight Sciences, Inc. (NASDAQ:SGHT) Q2 2025 Earnings Call TranscriptAugust 9, 2025 | msn.comSight Sciences, Inc. (SGHT) Q2 2025 Earnings Call TranscriptAugust 8, 2025 | seekingalpha.comSight Sciences Reports Q2 2025 Financial ResultsAugust 8, 2025 | tipranks.comCompared to Estimates, Sight Sciences (SGHT) Q2 Earnings: A Look at Key MetricsAugust 7, 2025 | zacks.comSight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue EstimatesAugust 7, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 2025POSC, MBOT, NYXH, and SGHT Company DescriptionsMicrobot Medical NASDAQ:MBOT$4.05 +0.16 (+4.22%) As of 03:44 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.Nyxoah NASDAQ:NYXH$5.28 -0.27 (-4.86%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.Positron OTCMKTS:POSC$1.60 +0.08 (+5.26%) As of 01:32 PM EasternPositron Corporation, a nuclear medicine healthcare company, specializes in the business of cardiac positron emission tomography (PET) imaging in the United States. It offers attrius PET scanner, clinical and technical services, and financing solutions enables healthcare providers to accurately diagnose cardiac disease, improve patient outcomes, and practice cost effective medicines. Positron Corporation was incorporated in 1983 and is based in Niagara Falls, New York.Sight Sciences NASDAQ:SGHT$3.49 -0.13 (-3.59%) As of 03:43 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Intel's Silent Comeback: 3 Pillars the Market Is Overlooking Palantir’s Defense Partnerships Fuel Its Growth Story It May Be Time to Buy the Dip in Texas Instruments Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
